首页> 外文OA文献 >Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Clinical evaluation of prognostic and metabolic benefits of Metformin in prostate cancer

【2h】

Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Clinical evaluation of prognostic and metabolic benefits of Metformin in prostate cancer

机译：生物标志物在代谢综合征男性患者前列腺癌中的临床应用：二甲双胍对前列腺癌预后和代谢益处的临床评价

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rhee, Handoo; Vela, Ian; Gunter, Jennifer; Jovanovic, Lidija; Hollier, Brett; Williams, Elizabeth; Wood, Simon; Ho, Ken; Nelson, Colleen;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome [J] . Hammarsten Jan* Current Hypertension Reviews . 2006,第4期

机译：良性前列腺增生症和临床前列腺癌-代谢综合征的两个新组成部分
2. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2eu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit [J] . Anastasopoulou Eleftheria A., Voutsas Ioannis F., Keramitsoglou Theodora, Cancer immunology, immunotherapy : . 2015,第9期

机译：一项针对接受AE37 Ii-key-HER-2 / neu多肽疫苗治疗的前列腺癌患者的初步研究表明，HLA-A * 24和HLA-DRB1 * 11等位基因可能是预后和预测性生物标志物，对临床有益
3. Prognostic value of metabolic parameters and clinical impact of F-18-fluorocholine PET/CT in biochemical recurrent prostate cancer [J] . Colombie M., Campion L., Bailly C., European Journal of Nuclear Medicine and Molecular Imaging . 2015,第12期

机译：F-18-氟胆碱PET / CT代谢参数对生化复发性前列腺癌的预后价值及其临床影响
4. THE CRRELATION OF THE METABOLIC SYNDROME AND PROSTATE CANCER: A molecular based evidence approach at the protein level [C] . Theodoros I. Roumeliotis, Sam larkin, Bashar Zeidan, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：代谢综合征和前列腺癌的相关性：蛋白质水平的基于分子的证据方法
5. Development of novel biomarkers in cancer: Detection of circulating miR-141 as a potential prognostic marker for prostate cancer. [D] . Gonzales, Jason Cadaoas. 2010

机译：癌症中新型生物标志物的开发：检测循环miR-141作为前列腺癌的潜在预后标志物。
6. Clinical association of metabolic syndrome C‐reactive protein and testosterone levels with clinically significant prostate cancer [O] . Enrique Gómez‐Gómez, Julia Carrasco‐Valiente, Juan Pablo Campos‐Hernández, 2019

机译：代谢综合征C反应蛋白和睾丸激素水平与临床上重要的前列腺癌的临床关联
7. Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in diagnosing localised prostate cancer [O] . Rhee, H., Heathcote, P., Wood, S., 2015

机译：生物标志物在代谢综合征男性前列腺癌中的临床应用项目：前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）在诊断局限性前列腺癌中的应用
8. Lifestyle Interventions for Four Conditions: Type 2 Diabetes, Metabolic Syndrome, Breast Cancer, and Prostate Cancer. Technology Assessment Report [R] . Sumamo, E., Ha, C., Korownyk, C., 2011

机译：四种情况的生活方式干预：2型糖尿病，代谢综合征，乳腺癌和前列腺癌。技术评估报告

Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Clinical evaluation of prognostic and metabolic benefits of Metformin in prostate cancer

著录项

相似文献

相关主题

期刊订阅